Will Eli Lilly's new weight loss drug Zepbound sell >$2B in the US by 2025? (first full year on the market)
5
110Ṁ1249resolved Feb 16
Resolved
YES1D
1W
1M
ALL
This market will resolve to YES if Zepbound has sold at least $2 billion in the US after its first 4 full quarters on the market. The evaluation criteria will be Eli Lilly's Annual Report for FY 2024. This is expected to be available in February 2025.
This question is managed and resolved by Manifold.
Get
1,000 to start trading!
1,000🏅 Top traders
| # | Name | Total profit |
|---|---|---|
| 1 | Ṁ67 | |
| 2 | Ṁ10 | |
| 3 | Ṁ5 | |
| 4 | Ṁ2 | |
| 5 | Ṁ1 |
Related questions
Related questions
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance
Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025
42% chance
Will Pfizer announce a weight loss drug competing with Ozempic and Wygovy before 12/31/2024?
35% chance
Will Retatrutide (new obesity drug) be FDA approved by the end of 2025?
36% chance
Will a large insurance company cover weight loss drugs before 2027?
86% chance
Of the companies which are currently #11-20 in market cap, will any be larger than Eli Lilly (#10) at the end of 2024?
81% chance
Affordable weight loss drugs before 2030?
76% chance
💊Will FDA approve 50 or more novel drugs in 2025?
76% chance
Will Suzetrigine/VX-548 (non-opioid painkiller) be prescribed to >500k patients in 2025?
48% chance